Ignite Creation Date:
2025-12-24 @ 11:52 AM
Ignite Modification Date:
2026-01-01 @ 8:04 AM
Study NCT ID:
NCT05485961
Status:
RECRUITING
Last Update Posted:
2025-12-22
First Post:
2022-07-29
Is NOT Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
Combined Dose-Finding and CV Outcomes Study With CSL300 (Clazakizumab) in Adult Subjects With ESKD Undergoing Dialysis
Sponsor:
CSL Behring
Organization:
Key Dates - Follows AllAPIJSON File Order
Start Date:
2022-10-21
Start Date Type:
ACTUAL
Primary Completion Date:
2029-08-30
Primary Completion Date Type:
ESTIMATED
Completion Date:
2029-08-30
Completion Date Type:
ESTIMATED
First Submit Date:
2022-07-29
First Submit QC Date:
None
Study First Post Date:
2022-08-03
Study First Post Date Type:
ACTUAL
Results First Submit Date:
None
Results First Submit QC Date:
None
Results First Post Date:
None
Results First Post Date Type:
None
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
None
Disp First Post Date Type:
None
Last Update Submit Date:
2025-12-19
Last Update Post Date:
2025-12-22
Last Update Post Date Type:
ESTIMATED